Author
Abstract
The development of antibiotic resistance by pathogenic microorganisms have necessitated the quest for alternative drug therapy. The efficacy and safety of extract from Citrus limon for the development of alternative antibacterial drug using the cold-pressing extraction methods and column chromatography to obtain crude juice extracts and fractions respectively while the agar well diffusion and tube dilution methods were used to screen the juice extract and fractions for antibacterial activity against Salmonella enterica, Klebsiella pneumoniae, Streptococcus pneumoniae and Streptococcus pyogenes. A total of 277.5mL (12.313%) of juice was obtained from 2253.8g of fruit while the phytochemical analysis revealed the presence of 10 phytocomponents namely tannins, flavonoids, anthraquinones, alkaloids, steroids, phenols, cardiac glycoside, terpenes, resins and saponins. One hundred percent (100%) of the juice crude extract exhibited the highest activity with mean inhibition zones (MIZ) ranged from 25.00±0.57mm to 32.33±0.33mm while 25% (6.67±1.15mm to 10.00±1.00mm) exhibited the least activity. The minimum inhibitory concentration and minimum bactericidal concentration (MIC and MBC) for the juice crude extract ranged from 25% to 12.5% and 100% respectively while S. paratyphi C, S. typhi, K. pneumoniae and S. pneumoniae were still viable at 100%. Out of the three fractions eluted, only one (JEtOAc) was active against all the test organisms with MIZ ranged from 14.00±0.33mm to 22.33±1.20mm while 27 compounds were identified in the fractions by GCMS. Notable group of compounds identified include fatty acids, terpenes, aliphatic and aromatic hydrocarbons. The MIC and MBC for the fractions ranged from 30mg/mL to 15mg/mL and >120mg/mL to 30mg/mL. Based on these findings, it can therefore be concluded that the juice extract and ethyl acetate fraction of Citrus limon possess antibacterial activity due to the abundant presence of secondary metabolites and it is recommended that toxicity test be carried out on the crude extract and fraction for the development of alternative drugs for the control and treatment of infections caused by resistant organisms.
Suggested Citation
Handle:
RePEc:epw:ejbio0:v:1:y:2020:i:1:id:17012
DOI: 10.24018/ejbio.2020.1.1.12
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:epw:ejbio0:v:1:y:2020:i:1:id:17012. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Support Team (email available below). General contact details of provider: https://eu-opensci.org/index.php/ejbio .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.